Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated C and is the 68th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
QGEN	QIAGEN NV	$10.26B	217,685,000	73.65%	0.00%
FONR	FONAR CORP	$95.83M	6,585,978	46.11%	3.58%
ILMN	ILLUMINA INC	$13.76B	158,300,000	93.34%	6.66%	Net Selling	Net Buying
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$7.34B	49,115,712	96.73%	3.27%	Net Buying	Net Buying
DHR	DANAHER CORP	$143.61B	715,669,594	75.32%	24.68%	Net Selling	Net Selling
A	AGILENT TECHNOLOGIES INC	$33.26B	284,064,728	87.38%	1.23%	Net Buying	Net Selling
RVTY	REVVITY INC	$11.02B	117,869,660	95.74%	2.70%	Net Selling	Net Selling
WAT	WATERS CORP	$20.37B	59,509,089	92.13%	7.87%	Net Selling	Net Selling
SHC	SOTERA HEALTH CO	$3.24B	283,855,074	67.09%	32.91%	Net Selling
LH	LABCORP HOLDINGS INC	$21.86B	83,700,000	91.54%	1.53%	Net Selling	Net Selling
IDXX	IDEXX LABORATORIES INC	$42.04B	80,421,917	91.33%	1.77%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$463.65M	92,177,383	91.64%	8.36%	Net Selling	Net Selling
DGX	QUEST DIAGNOSTICS INC	$20.12B	111,635,472	90.90%	1.78%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$629.88M	30,443,595	53.50%	42.54%	Net Selling	Net Selling
NTRA	NATERA INC	$22.58B	136,546,580	79.86%	20.14%	Net Selling	Net Selling
XGN	EXAGEN INC	$128.18M	18,002,416	34.65%	62.05%	Net Selling	Net Selling
MEDP	MEDPACE HOLDINGS INC	$8.57B	28,741,609	27.67%	72.33%	Net Buying	Net Buying
MYNZ	MAINZ BIOMED NV	$4.24M	2,319,353	10.08%	0.00%
MTD	METTLER TOLEDO INTERNATIONAL INC	$24.01B	20,782,786	95.33%	4.67%	Net Selling	Net Buying
EXAS	EXACT SCIENCES CORP	$10.10B	188,637,673	96.71%	3.29%	Net Selling	Net Selling
TMO	THERMO FISHER SCIENTIFIC INC	$152.04B	377,493,912	87.26%	0.89%	Net Selling	Net Selling
ACRS	ACLARIS THERAPEUTICS INC	$159.17M	108,281,239	58.99%	41.01%	Net Buying	Net Selling
IQV	IQVIA HOLDINGS INC	$27.14B	173,000,000	52.33%	47.67%	Net Selling
GH	GUARDANT HEALTH INC	$6.11B	123,888,045	65.38%	34.62%	Net Selling	Net Selling
ICLR	ICON PLC	$11.57B	79,464,252	93.00%	0.00%
NEO	NEOGENOMICS INC	$909.87M	128,694,503	72.29%	27.71%	Net Buying	Net Buying
PSNL	PERSONALIS INC	$530.83M	88,325,138	60.27%	39.73%	Net Buying	Net Selling
TWST	TWIST BIOSCIENCE CORP	$2.01B	59,916,141	88.23%	11.77%	Net Selling	Net Selling
STIM	NEURONETICS INC	$249.46M	65,820,344	25.85%	65.61%	Net Buying	Net Selling
GRAL	GRAIL INC	$1.49B	35,973,494	66.69%	27.33%	Net Buying	Net Selling
NDRA	ENDRA LIFE SCIENCES INC	$2.55M	738,370	0.09%	99.91%	Net Buying
CDNA	CAREDX INC	$1.04B	55,680,549	78.78%	21.22%	Net Selling	Net Selling
NOTV	INOTIV INC	$76.26M	34,352,978	23.56%	39.40%	Net Buying	Net Selling
SERA	SERA PROGNOSTICS INC	$64.42M	37,672,784	53.70%	25.93%	Net Selling	Net Selling
RDNT	RADNET INC	$4.16B	75,030,098	68.93%	31.07%	Net Selling	Net Selling
APDN	APPLIED DNA SCIENCES INC	$2.03M	433,186	2.06%	97.94%
OPK	OPKO HEALTH INC	$1.05B	793,052,803	23.51%	76.49%	Net Buying	Net Buying
NEOG	NEOGEN CORP	$1.20B	217,038,267	98.51%	1.49%	Net Buying	Net Buying
LAB	STANDARD BIOTOOLS INC	$398.81M	379,822,268	56.19%	43.81%	Net Buying	Net Selling
DRIO	DARIOHEALTH CORP	$29.27M	43,949,424	16.78%	38.44%	Net Buying
CSTL	CASTLE BIOSCIENCES INC	$541.36M	28,872,315	85.10%	14.90%	Net Selling	Net Selling
VNRX	VOLITIONRX LTD	$65.93M	103,022,677	20.39%	35.53%	Net Buying	Net Buying
OCX	ONCOCYTE CORP	$75.79M	28,599,285	16.42%	83.58%	Net Buying
PRPO	PRECIPIO INC	$16.41M	1,512,011	0.46%	99.54%	Net Buying	Net Buying
STRR	STAR EQUITY HOLDINGS INC	$6.35M	3,209,340	0.59%	99.41%	Net Buying
MDXH	MDXHEALTH SA	$9.90M	49,497,334	22.81%	77.19%
BNR	BURNING ROCK BIOTECH LTD	$41.17M	107,616,506	2.04%	0.00%
ADVB	ADVANCED BIOMED INC	$20.77M	21,640,000	0.05%	0.00%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$7.49M	27,249,462	1.88%	17.65%
ISPC	ISPECIMEN INC	$2.65M	2,496,858	0.92%	99.08%
XWEL	XWELL INC	$5.00M	5,261,024	1.27%	98.73%	Net Buying
TRIB	TRINITY BIOTECH PLC	$11.40M	359,193,482	0.23%	0.00%
PRPH	PROPHASE LABS INC	$13.75M	41,541,205	12.02%	24.84%
CHEK	CHECK-CAP LTD	$4.33M	5,851,042	1.59%	0.00%
PRE	PRENETICS GLOBAL LTD	$91.15M	13,002,975	8.84%	0.00%
BDSX	BIODESIX INC	$42.06M	146,563,031	36.42%	55.77%	Net Buying	Net Buying

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Jun 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Qiagen Nv (NYSE:QGEN) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: C.

Qiagen Nv (NYSE:QGEN) has a Due Diligence Score of 25, which is -2 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates QGEN as a "A".

QGEN passed 10 out of 38 due diligence checks and has weak fundamentals. Qiagen Nv has seen its stock return 8.67% over the past year, overperforming other diagnostic & research stocks by 32 percentage points.

Qiagen Nv has an average 1 year price target of $46.33, a downside of -1.65% from Qiagen Nv's current stock price of $47.11.

Qiagen Nv stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering Qiagen Nv, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 12 points higher than the diagnostic & research industry average of 27.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -3% over the past year, overperforming other diagnostic & research stocks by 20 percentage points.

3. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: A, Momentum: F, Sentiment: C, Safety: B, Financials: B, and AI: C.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 20, which is -7 points lower than the diagnostic & research industry average of 27. Although this number is below the industry average, our proven quant model rates ILMN as a "B".

ILMN passed 6 out of 33 due diligence checks and has weak fundamentals. Illumina has seen its stock lose -20.41% over the past year, overperforming other diagnostic & research stocks by 3 percentage points.

Illumina has an average 1 year price target of $105.20, an upside of 21.02% from Illumina's current stock price of $86.93.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.28%, which is 1 percentage points higher than the diagnostic & research industry average of 0.61%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 38.1% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.83%, which is the same as the diagnostic & research industry average of 0.61%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 33% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.61%, which is the same as the diagnostic & research industry average of 0.61%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 23.8% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.73% in the last day, and up 0.1% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are down.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 57, which is 42 points higher than the diagnostic & research industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Icon's stock has dropped -54.18% in the past year. It has underperformed other stocks in the diagnostic & research industry by -31 percentage points.

2. Thermo Fisher Scientific (NYSE:TMO)

Thermo Fisher Scientific (NYSE:TMO) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Thermo Fisher Scientific has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Thermo Fisher Scientific's stock has dropped -29.66% in the past year. It has underperformed other stocks in the diagnostic & research industry by -7 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 56 points higher than the diagnostic & research industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -3% in the past year. It has overperformed other stocks in the diagnostic & research industry by 20 percentage points.

Are diagnostic & research stocks a good buy now?

47.62% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 17.5% over the next year.

4.88% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 4.88% of diagnostic & research stocks are rated B (Buy), 70.73% are rated C (Hold), 19.51% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 19.9x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.